On behalf of the Board, it gives me great pleasure to offer you this opportunity to invest in Chimeric Therapeutics
Limited (Chimeric or the Company).
Through this Prospectus, the Company is inviting investors to subscribe for a minimum of 175,000,000 New
Shares, at an Offer Price of $0.20 per New Share. The Company will have a market capitalisation of $66,105,280
on completion of the Offer assuming the Minimum Subscription Amount has been met. The Offer is managed by
Bell Potter Securities Limited and Baker Young Limited.
The funds raised by this Offer will provide Chimeric with working capital to support its growth strategy and will
fund payments under the Company’s Licence Agreement with City of Hope as well as Phase I clinical trials. An
ASX listing will provide Chimeric with access to equity capital markets, facilitate corporate transactions by the
issue of shares and provide liquidity for Existing Shareholders.
The focus of the Company’s activities will be the development of an exciting class of cell therapy cancer
drugs known as CAR Ts, an acronym for Chimeric Antigen Receptor T Cell. These drugs have shown dramatic
results in blood cancers and there are now three CAR T drugs on the market approved by the US Food and
Drug Administration (FDA).
Chimeric’s CAR T technology, known as CTLX-CAR T, has completed many years of pre-clinical research and in
September 2020 dosing of patients with glioblastoma (brain cancer) commenced as part of Phase 1 clinical
trials at City of Hope Cancer Centre in Los Angeles.
Chimeric has the worldwide exclusive licence to technology from City of Hope pursuant to a Licence Agreement,
details of which are set out in section 9.4 of this Prospectus.
The Directors believe Chimeric will be the only company listed on the ASX conducting human clinical trials with
CAR T cell therapy.
The scientific founders of the technology, Professors Christine Brown and Michael Barish, are accomplished
scientists of high renown in the CAR T scientific community.
Chimeric has recruited an outstanding US based senior management team. The Chief Operating Officer,
Ms Jennifer Chow was, until recently, the Head of Global Marketing, Analytics and Commercial Operations at
Kite Pharma one of the world’s leading CAR T companies with the distinction of having two of the only three
FDA approved CAR T drugs. Our Chief Medical Officer, Dr Syed Rizvi, was until recently the Chief Medical Officer
at CAR T leader, Legend Biotech, which was the largest biotech listing on NASDAQ this year. Both have prior
experience working together at Celgene Corporation.
The Board comprises experienced and seasoned, life science-focused Directors with relevant cell therapy and
glioblastoma domain expertise.
Chimeric has negotiated a long term Sponsored Research Agreement with City of Hope which provides Chimeric
with access to the laboratory, facilities and scientific team of the technology founders, Professors Brown and
Barish, to further develop Chimeric’s CAR T technology. Further details of the Sponsored Research Agreement
are provided at section 9.5.
To fund its growth plan, Chimeric is seeking to raise a minimum of $35 million through the issue of 175,000,000
New Shares at a price of $0.20 per New Share pursuant to the Offer.
This Prospectus contains detailed information about the Company’s operations, financial performance,
experienced management team and future plans, and Chimeric’s business model and key dependencies relevant
to the business model. It also outlines the potential risks associated with this investment (set out in detail in
section 6). Some of those risks include:
(a) access to the intellectual property rights to develop and commercialise CAR T cells in the field of oncology
is predicated on the continuing operation of the Licence Agreement between Chimeric and City of
Hope Cancer Centre;
(b) Chimeric’s ability to achieve profitability is dependent on its ability to complete successful clinical trials,
obtain regulatory approval for the CAR T technology and successfully commercialise that product. There
is no guarantee that Chimeric’s product will be commercially successful; and
(c) Chimeric depends on the talent and experience of its personnel as its primary asset. There may be a
negative impact on Chimeric if any of its key personnel leave.
I encourage you to read and understand the Prospectus, and seek independent professional advice as
necessary, before making an investment decision. Any investment in Chimeric should be considered speculative.
Call the Chimeric Information Line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia)
between 9:00am and 5:00pm AEST if you have any questions in relation to the Offer.
I look forward to welcoming you as a shareholder.
MR PAUL HOPPER
Chimeric Therapeutics Limited